Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Achieve Life Sciences Inc (ACHV – Research Report) yesterday and set a price target of $6. The company’s shares closed yesterday at $2.50.
“We are initiating coverage of $6 price target. Achieve is developing cytisinicline (cytisine: CYT) as a smoking cessation aid.”
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -20.6% and a 21.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Achieve Life Sciences Inc with a $13 average price target, representing a 420.0% upside. In a report issued on June 11, Ladenburg also reiterated a Buy rating on the stock with a $20 price target.
The company has a one-year high of $6.10 and a one-year low of $1.04. Currently, Achieve Life Sciences Inc has an average volume of 543.1K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.